Plain-English translation of NCT07514832 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination chemotherapy called VA-CIG—which includes venetoclax, azacitidine, idarubicin, and low-dose cytarabine plus a growth factor—as a first-line treatment for acute myeloid leukemia (AML), a serious blood cancer. The study aims to see how well the medication works and how safe it is for newly diagnosed patients who are fit enough to receive intensive chemotherapy. About 48 patients will receive this treatment across multiple medical centers.
Acute myeloid leukemia is a fast-growing blood cancer that requires aggressive treatment. Researchers are testing this medication combination to see if it can improve survival rates and treatment outcomes for patients who have never been treated for AML before.
You likely qualify if…
You likely don't qualify if…
You will receive the four-drug combination chemotherapy regimen at a hospital or treatment center as part of induction therapy (the first major treatment phase for AML). The trial will monitor your response to treatment, side effects, and overall health through blood tests, heart imaging, and regular clinical visits. The exact schedule and duration will be determined by your medical team based on your individual response and any changes to your condition.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China